Related Experiment Video
Updated: Jul 19, 2026
09:33
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Ceramide: a central regulator in Alzheimer's disease pathogenesis
Priyanka Choudhary1, Shilpa Kumari2, Kajal Bagri2
1Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda, Punjab, 151001, India.
Inflammopharmacology
|March 28, 2025
Summary
Elevated ceramide levels worsen Alzheimer
Area of Science:
- Neuroscience
- Biochemistry
- Cell Biology
Background:
- Ceramide is a vital sphingolipid involved in cellular signaling and nervous system health.
- Sphingolipids, including ceramide, play critical roles in neuronal differentiation and development.
- Ceramide metabolism is increasingly implicated in aging and neurodegenerative conditions.
Purpose of the Study:
- To elucidate the molecular pathways linking ceramide metabolism and accumulation to Alzheimer's disease (AD) pathology.
- To detail the cellular and pathological mechanisms by which ceramide impacts AD pathophysiology.
- To explore the potential of targeting ceramide metabolism for novel therapeutic strategies against AD and cognitive decline.
Main Methods:
- This review synthesizes existing research on ceramide metabolism in the context of AD.
- Analysis of molecular pathways involving ceramide, amyloid-beta, and tau pathology.
- Examination of ceramide's role in neuroinflammation, oxidative stress, and insulin resistance in AD.
Main Results:
- Increased intracellular ceramide production and accumulation are observed during aging and in AD.
- High ceramide levels exacerbate AD pathology by promoting amyloid-beta (Aβ) aggregation and tau hyperphosphorylation.
- Ceramide dysregulation contributes to neuroinflammation, oxidative stress, and insulin resistance in the brain.
Conclusions:
- Ceramide accumulation is a significant driver of Alzheimer's disease progression.
- Understanding ceramide's role offers potential therapeutic targets for AD and age-related cognitive decline.
- Targeting ceramide metabolism may provide novel treatment strategies for neurodegenerative diseases.
More Related Videos
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
06:41Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Role of Neurotransmitters in Memory
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...